HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forced OTC Switch Impact On Consumers “Ambiguous” – MIT’s Berndt

This article was originally published in The Tan Sheet

Executive Summary

The impact of forced Rx-to-OTC switches on consumers "is uncertain and ambiguous and there is no clear gain in social welfare," MIT economics professor Ernst Berndt, PhD, says in recent comments to FDA

You may also be interested in...



OTC Claritin Access Needs Study Before Other Switches Are Forced – Pfizer

FDA should evaluate whether OTC Claritin has increased access and lowered costs for allergy sufferers before deciding whether to require the other second-generation antihistamines to switch OTC, Pfizer asserts in May 7 comments to the agency

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

RS129410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel